Scroll through recent research or click the category icon to the right of each title for similar research summaries. If you would like more background context on a particular piece of research, please click the link next to the “Reading Room Guide,” the small character at the bottom-left of each research story. He will transport you to the appropriate page in Autism Reading Room. You can access original publication sources and other popular media articles by clicking the news buttons at the bottom-right of each summary.
Largest Study to Date Finds Autism Is Mostly Heritable
By Chelsea Toledo, M.A. on August 15, 2019
Background: Autism Spectrum Disorder (ASD) can be caused by multiple risk factors. Risk factors increase the likelihood of developing a condition and can be genetic or environmental. Genetic risk factors relate to variations in our DNA, while environmental factors stem from social, physical, or chemical exposures and can be present during fetal development or months to years after birth.
What’s New: A recent study set out to determine the nature of the risk factors that were most commonly associated with an ASD diagnosis. The authors analyzed the largest-ever dataset for this purpose – containing medical information for more than 2 million births from five different countries: Denmark, Finland, Sweden, Israel, and Western Australia.
Looking at multiple generations represented within the dataset, the researchers found:
- In total, 22,156 ASD diagnoses were recorded within the sample (about 1 percent).
- Overall, more than 80 percent of ASD cases were found to be heritable.
- Heritability varied by country, ranging from 50.9 percent heritability in Finland to 86.8 percent heritability in Israel.
- Maternal effects (such as illness during pregnancy) were associated with only about 1 percent of causes.
- Other environmental risk factors were found to have an additive effect with genetics.
Why it’s important: This is the largest-ever study to suggest that ASD is largely genetic. As this study suggests, environmental factors interact with genetic risk factors and their association with ASD varies by country – a pattern that merits future study.
Help me understand :
Eye-Tracking Study in Infants Finds Pattern for ASD
By Chelsea Toledo, M.A. on June 12, 2019
Background: Autism spectrum disorder (ASD) is characterized by differences in communication, social interaction and behavior. Although the average age for a child to receive an ASD diagnosis is 4 years old, researchers have uncovered patterns in infants and toddlers who go on to be diagnosed. One potential indicator among the youngest children is differences in visual attention, or gaze.
What’s New: A recent study identified patterns in the joint attention – the process of looking at something alongside another person – among 10-month-old infants. The researchers conducted a series of tasks with 112 infants, 81 of whom had older siblings with ASD. Tasks were designed to assess the infants’ response to cues for joint attention (such as turning to look at a puppet), as well as how the infants initiated joint attention themselves (such as giving the infant an opportunity to point at flashing lights).
Repeating the assessments at 14 and 18 months and following up at 36 months, the researchers found:
- 22 of the children whose older siblings had ASD were later diagnosed, as well.
- Responses to cues for joint attention were not linked to rates of ASD diagnoses, but were linked to familial risk (i.e., infants who had older siblings with ASD were more likely to have low scores on this task, whether or not they were ultimately diagnosed themselves).
- The infants’ tendency to initiate joint attention was markedly different among those ultimately diagnosed with ASD, who had both lower scores in this area and atypical development of this skill between 10 and 18 months.
Why it’s important: This study suggests observable indicators of ASD may appear as early as 10 months of age. Future research could lead to earlier diagnosis and intervention.
Help me understand :
Molecular Biomarker May Predict GI Symptoms in ASD
By Chelsea Toledo, M.A. on April 26, 2019
Background: For decades, researchers have suspected a link between Autism Spectrum Disorder (ASD) and gastrointestinal (GI) symptoms. The GI symptoms frequently reported in ASD include abdominal pain, constipation, chronic diarrhea, and gastroesophageal reflux disease. Some people with ASD also experience inflammation of the intestines, which respond at various rates to anti-inflammatory therapies.
What’s New: A recent study identified a biomoarker with the potential to predict which individuals with ASD and GI issues would respond quickly or more slowly to anti-inflammatory treatment. The researchers conducted molecular analyses of colon tissue samples from 35 children with ASD. Twenty of those children were found previously to respond slowly to oral anti-inflammatory medicines for GI symptoms, and 15 were fast responders.
Focusing on differences in the early stages of gene expression, the researchers found:
- Fast responders with constipation experienced timely relief after anti-inflammatory therapy, whereas constipation persisted on the right side of slow responders’ colons after treatment.
- Fast responders had greater activity of genetic material related to inflammatory and immune responses
- Slow responders had an increased number of genetic pathways related to the movement of the colon
- The presence of a single molecule could predict whether the children were slow responders to anti-inflammatory therapy.
Why it’s important: This study revealed underlying differences in genetic expression within a group of children with ASD that resulted in predictable GI outcomes. Further research may lead to specialized therapy for people with ASD and GI symptoms.
Help me understand :
Abilify Effective Against Behavioral Symptoms of ASD
By Chelsea Toledo, M.A. on February 27, 2019
Background: While no standardized treatment exists to treat the symptoms of Autism Spectrum Disorder (ASD), a range of therapeutic strategies may be employed, depending on the specifics of a particular ASD case. Because of the overlap between ASD and certain mental health conditions, some research has focused on the possibility of treating ASD with existing pharmaceutical therapies.
What’s New: A recent review compiled evidence from a series of clinical studies and trials evaluating the safety and efficacy of the drug aripiprazole in treating people with ASD. Aripiprazole, manufactured by Otsuka under the brand name Abilify, is an antipsychotic drug commonly used to treat the symptoms of schizophrenia, bipolar disorder, Tourette’s syndrome, and major depression. In recent years, aripiprazole was approved by the U.S. Food and Drug Administration (FDA) to treat irritability in children and adolescents with ASD.
Combining the results from three studies evaluating results in 408 participants between 1995 and 2017, the researchers found:
- Aripiprazole was safe and well-tolerated among the study participants.
- Aripiprazole was effective in treating behavioral ASD symptoms, including irritability, hyperactivity, noncompliance, and repetitive movements.
- Aripiprazole was not effective in treating lethargy or social withdrawal in participants with ASD.
Why it’s important: This article suggests that aripiprazole may be an effective treatment strategy for some people with behavioral issues related to ASD. Future research on a larger sample of individuals could clarify the best contexts for leveraging aripiprazole.
Help me understand :